Constitutive CD40 Signaling in Dendritic Cells Limits Atherosclerosis by Provoking Inflammatory Bowel Disease and Ensuing Cholesterol Malabsorption.

[1]  V. D’Agati,et al.  Cholesterol Accumulation in Dendritic Cells Links the Inflammasome to Acquired Immunity. , 2017, Cell metabolism.

[2]  B. Stecher,et al.  CD40-signalling abrogates induction of RORγt+ Treg cells by intestinal CD103+ DCs and causes fatal colitis , 2017, Nature Communications.

[3]  K. Bornfeldt,et al.  Macrophage Phenotype and Function in Different Stages of Atherosclerosis. , 2016, Circulation research.

[4]  M. Cybulsky,et al.  Macrophages and Dendritic Cells: Partners in Atherogenesis. , 2016, Circulation research.

[5]  G. Hansson,et al.  Adaptive Response of T and B Cells in Atherosclerosis. , 2016, Circulation research.

[6]  C. Weber,et al.  Regulation of atherosclerotic plaque inflammation , 2015, Journal of internal medicine.

[7]  Y. Darif,et al.  The Contribution of CD40/CD40L Axis in Inflammatory Bowel Disease: An Update , 2015, Front. Immunol..

[8]  C. Hedrick.  Lymphocytes in atherosclerosis. , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[9]  Steffen Jung,et al.  Development and function of dendritic cell subsets. , 2014, Immunity.

[10]  A. Tedgui,et al.  Adaptive (T and B Cells) Immunity and Control by Dendritic Cells in Atherosclerosis , 2014, Circulation research.

[11]  P. Libby,et al.  Immune effector mechanisms implicated in atherosclerosis: from mice to humans. , 2013, Immunity.

[12]  Lieping Chen,et al.  Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.

[13]  E. Lutgens,et al.  Inflammation and immune system interactions in atherosclerosis , 2013, Cellular and Molecular Life Sciences.

[14]  Oliver Soehnlein,et al.  Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile , 2010, The Journal of experimental medicine.

[15]  M. Cybulsky,et al.  Resident Intimal Dendritic Cells Accumulate Lipid and Contribute to the Initiation of Atherosclerosis , 2010, Circulation research.

[16]  L. Beckers,et al.  The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis. , 2009, Seminars in immunology.

[17]  F. Ginhoux,et al.  Conventional Dendritic Cells at the Crossroads Between Immunity and Cholesterol Homeostasis in Atherosclerosis , 2009, Circulation.

[18]  M. Croft.  The role of TNF superfamily members in T-cell function and diseases , 2009, Nature Reviews Immunology.

[19]  P. Libby,et al.  CD11c+ Dendritic Cells Maintain Antigen Processing, Presentation Capabilities, and CD4+ T-Cell Priming Efficacy Under Hypercholesterolemic Conditions Associated With Atherosclerosis , 2008, Circulation research.

[20]  K. Rajewsky,et al.  Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-κB pathway and promotes lymphomagenesis , 2008, The Journal of experimental medicine.

[21]  K. Rajewsky,et al.  LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. , 2008, Blood.

[22]  B. Reizis,et al.  Notch–RBP-J signaling controls the homeostasis of CD8− dendritic cells in the spleen , 2007, The Journal of experimental medicine.

[23]  A. Gasbarrini,et al.  TNF-α Blockade Down-Regulates the CD40/CD40L Pathway in the Mucosal Microcirculation: A Novel Anti-Inflammatory Mechanism of Infliximab in Crohn’s Disease1 , 2006, The Journal of Immunology.

[24]  F. Powrie,et al.  Essential role for CD103 in the T cell–mediated regulation of experimental colitis , 2005, The Journal of experimental medicine.

[25]  P. Rutgeerts,et al.  Safety and tolerability of antagonist anti‐human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease , 2005, Alimentary pharmacology & therapeutics.

[26]  M. Scarpa,et al.  The role of CD40 in ulcerative colitis: histochemical analysis and clinical correlation , 2002, European journal of gastroenterology & hepatology.

[27]  H. Niederegger,et al.  Network of Vascular-Associated Dendritic Cells in Intima of Healthy Young Individuals , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[28]  M. Daemen,et al.  Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Libby,et al.  Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Rutgeerts,et al.  Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions1 , 2000, The Journal of Immunology.

[31]  R. Virmani,et al.  Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[32]  G. Camussi,et al.  Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease , 1999, American Journal of Gastroenterology.

[33]  M. Daemen,et al.  Requirement for CD154 in the progression of atherosclerosis , 1999, Nature Medicine.

[34]  P. Rutgeerts,et al.  Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. , 1999, Journal of immunology.

[35]  P. Libby,et al.  Reduction of atherosclerosis in mice by inhibition of CD40 signalling , 1998, Nature.

[36]  I. Tabas,et al.  Dendritic cells in atherosclerosis , 2013, Seminars in Immunopathology.

[37]  H. Milionis,et al.  An overview of lipid abnormalities in patients with inflammatory bowel disease , 2011, Annals of gastroenterology.